# NanoSyrinx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanosyrinx

- Industry: Biotechnology
- Headquarters: Coventry, UK
- Website: www.nanosyrinx.com
- Total disclosed funding: $4.9M
- Latest round: Seed (Jul 17, 2021)
- Investors on record: 5

## About

Based in Coventry, UK, and founded in 2018, NanoSyrinx Ltd. operates as a biotechnology company that develops new cell engineering tools for novel therapeutic modalities. The company was co-founded by CEO Mr. Joe Healey, Dr. Alexia Hapeshi, and Dr. Nicholas Waterfield. In July 2021, NanoSyrinx Ltd. raised GBP 6.2 million in Seed funding from Octopus Ventures and M Ventures.

NanoSyrinx Ltd. develops a platform for unmet biotechnological and therapeutic needs. The company's platform genetically encoded drug delivery system, making use of naturally occurring ‘nanosyringes’. The NanoSyrinx platform utilizes a core ‘chassis’ of several genes, the antibody cell specificity/binding protein, which can be engineered using standard lab molecular biology techniques. And the protein/peptide payloads are fused into the genetic construct and targeted to load in the nanosyringe at the synthesis stage.

## Funding rounds

- Seed, Jul 17, 2021, $4.9M — IQ Capital, Octopus Investments, M Ventures, BioCity Group Ltd., UK Innovation & Science Seed Fund

## Investors

- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Seed
- Octopus Investments (https://capitalatlas.ai/funds/octopus-investments) — Seed
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed
- BioCity Group Ltd. — Seed
- UK Innovation & Science Seed Fund (https://capitalatlas.ai/funds/uk-innovation-science-seed-fund) — Seed